Drugs / Recombinant human soluble IL-4 receptor
Recombinant human soluble IL-4 receptor
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00017693 | May 1998 → Feb 2000 | asthma | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human soluble IL-4 receptor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00017693 ↗ |
| Known as | recombinant human soluble interleukin-4 receptor | “The current study evaluated the therapeutic potential of inhaled recombinant human soluble interleukin-4 receptor (IL-4R) as an IL-4 antagonist.” PMID 11398072 ↗ Jun 2001 |
| Known as | rsIL-4R | “Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks.” NCT00017693 ↗ |
| Action | Inhibit | “Binding and inactivating the IL-4 molecule with IL-4R may diminish the allergic asthmatic response by inhibiting activities of IL-4.” NCT00017693 ↗ |
| Route | Inhaled | “given by means of inhalation once weekly for 12 weeks.” NCT00017693 ↗ |